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This article reviews the mediation systems participat-
ing or potentially participating in inflammatory disease, 
especially in immunologic injury of the glomerulus. Me-
diator systems are separated into 3 mechanisms: the 
first involves complement and neutrophils; the second 
involves systems unrelated to neutrophils and comple-
ment components from C3 to C9; and the third involves 
blood monocytes. 
Major emphasis is given to an analysis of factors that 
potentially participate in the second mechanism. These 
include humoral factors such as the coagulation system 
and Hageman factor systems and cellular factors such 
as platelets or cells resident in the glomerulus. Studies 
on a role of vasoactive amines are presented. The impor-
tance of separ ating neutrophil-dependent and -indepen-
dent mechanisms in these s tudies is emphasized. 
A review of current knowledge of the biochemical 
mechanisms involved in the Hageman factor system is 
presented because of the potential role of these compo-
nents in the development of inflammation. 
Studies of inflammatory injury of tissue have focused on 
cellular and humoral mediation systems that are responsible 
for damage of cells, tissues, and supporting structures. Because 
these studies are representative of the depth of scientific pen-
etration in the area of inflammatory tissue injury, I discuss the 
known events participating in the injury of a readily studied 
target, the renal glomerulus. I also deal with recent events that 
have developed in the system of plasma proteins that form the 
Hageman factor (HF) pathway. This system comprises the 
kallikrein-kinin-forming, intrinsic clotting, and fibrinolytic sys-
tems. Together, the HF and complement systems of proteins 
constitute the major inflammatory mediator pathways of the 
plasma. 
MEDIATION OF INFLAMMATORY INJURY OF THE 
GLOMERULUS 
Immunologic injury of the renal glomerulus has been shown 
to result from the participation of several mediator systems. 
The first, which involves the activation of the complement 
system along the glomerular basement membrane (GBM), 
where the antigen-antibody reaction resides, is followed by the 
accumulation of circulating leukocytes, the release of injurious 
products of these cells, and injury to the GBM. Proteinuria 
results . A second mediation mechanism does not involve com-
plement and neutrophils, but some other plasma system as yet 
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unidentified. A third results from the accumulation of mono-
cytes or macrophages. In this manuscript a review of the data 
defining these 3 mediating mechanisms is presented. Because 
little is known about the second system listed, a discussion of 
the potentially important mediators is offered. 
NEUTROPHIL-DEPENDENT IMMUNOLOGIC INJURY 
OF THE GLOMERULUS 
The type of antibody reacting with antigen may decide which 
mediating mechanism is called into play. Co-workers and I 
demonstrated this phenomenon by obtaining nephrotoxic an-
tibody fmm sheep that were immunized with rabbit GBM. The 
antibody obtained 2 to 3 mo after the beginning of immunization 
produced glomerular injury in rabbits on intravenous injection. 
Neutrophils accumulated in the glomeruli 4 to 6 hl' after injec-
tion and displaced endothelial cells from their attachment to 
the underlying GBM (Fig 1) [1]. Proteinuria, which may be 
used as a measure of injUJ-y, commenced at that time. Occasion-
ally, we found that lysosomal granules were being discharged 
through the plasma membrane of the neutrophils against the 
GBM. Although no demonstrable alteration in the GBM was 
observed, fragments of it were detected in the urine [2]. In 
addition, cathepsin E and band 4 protein, both uniquely present 
in the neutrophil lysosomes of the rabbit, were also found in 
th~ urine at this time. Further studies indicated that lysosomal 
enzymes of neutrophils hydrolyzed isolated GBM of rabbits and 
man and that basic pept ides of the lysosomes induced increased 
vascular permeability (reviewed in reference 3, 4) . 
In chronic, autologous nephrotoxic nephritis in rabbits, neu· 
trophil depletion was found to diminish all aspects of the renal 
disease including proteinuria, fibrin deposition, crescent for· 
mation, and clearance functions [5). 
The mechanism of injury, involving antigen and antibody, 
complement, and neutrophils, is common to the arteritis of 
serum sickness, immunologic synovitis, and cutaneous vasculitis 
[3]. 
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The lesions are inhibited not only by depletion of neutrophils 
prior to complexing of antibody with antigen at the site of 
injury, but also by depletion of complement [1,3,6]. 
NEUTROPHIL-
INDEPENDENT IMMUNOLOGIC INJURY OF THE 
GLOMERULUS 
A second pathogenic mechanism of glomerular injury can 
only be described in negative terms. It is the injury occurring at 
the level of the GBM in the absence of neutrophil participation. 
This form of injury was defined when the observation of neu· 
trophil-dependent mechanisms was made. 
Neutrophil·Independent Injury of the Glomerulus in Anti-
Glomerular-Easement·Membrane (Nephrotox ic) Nephritis 
When we used sheep to produce neplU'otoxic antibodies for 
rabbits, we found that continued immunization of the sheep 
with rabbit GBM was accompanied by the development of anti· 
GBM antibodies that induced in1mediate proteinuria in th 
rabbit that was only partially inhibited by prior removal of th 
neutrophils. Larger amounts of this antibody induced protein· 
uria to the same degree as the early antibody, but in the absenc 
of neutrophil participation (Fig 2). 
We attempted to determine whether the antibod ies devel· 
oping later in the immunization schedule could be separated by 
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FIG 1. Electron photomicrograph of a glomerular capillary 4 hI' after 
injection of an'ti-GBM antibody. The neutrophil (PMN) has displaced 
the endotheli'a l cell (End) to gain access to the antibody and comple-
ment that lie along the glomerular basement membrane. BM = base-
ment membrane; L = lumen; Ep = epithelial cell. 
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FIG 2. Proteinuria developing as a function of antibody bound in the 
glomeruli of rabbits injected with sheep antirabbit glomerular basement 
membrane. The antisera were obtained 5 to 7 mo after immunization 
of sheep was stru·ted. Recipient rabbits were either normal or depleted 
of neutrophils (PMN-depleted) with nitrogen l11ustru'd as noted. 
class or subclass. Accordingly, globulin fractions of the antisera 
obtained after immunization of the sheep for 3 to 4 mo were 
obtained by .(NH4hSO" precipitation. These were then fraction-
ated by anion-exchange chromatography on DEAE-Sephadex 
A-50. The elution pattern of the protein is shown in Fig 3. The 
fractions collected were arbitrarily pooled as noted. 
We determined the quantity of antibody bound to rabbit 
GBM in each pool by coupling 1251 to the antibody globulin, 
injecting the labeled antibody into the rabbits intravenously, 
and then (2 hr after injection of the antibody) homogenizing 
and repeatedly washing the kidneys. The amount of ' ~5I anti-
body protein remaining firmly bound after 3 washings and 
homogenization was then determined by isotope counts. The 
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pools of antibody eluted from the DEAE-Sephadex were then 
tested individually in several ways: 
1. The ability of the antibody to induce proteinmia in 1.5-kg 
rabbits in the presence or absence of neutrophils (depleted with 
nitrogen mustard) . 
2. The class of antibody as determined immunologically. 
3. The complement-fixing capacity of the antibody. 
Pools 2, 4, and 5 contained antibody that induced proteinuria 
in rabbits as shown in Fig 4. When tested in neutrophil-depleted 
rabbits, the antibody in pool 2 induced proteinuria equally well 
in the presence or absence of neutrophils. The antibody in pools 
4 and 5, by contrast, induced proteinmia that was partially 
prevented by neutrophil depletion. 
Antibody globulin in pools 2, 4, and 5 were then examined 
immunologically with rabbit antibody to sheep IgG, and IgG2 
kindly provided by Dr. M. Hogarth. In immunoelectrophoresis, 
the immunoglobulins in pools 1 and 2 were of the Y2 type; 
immunoglobulins of pools 4 and 5 were of the y, type. 
Complement-fixation tests were then performed with each 
pool with isolated, purified rabbit GBM as an insoluble antigen. 
Graded doses of antibody were incubated with constant 
amounts of the antigen. The complex was then washed and 
fresh rabbit serum was added as a somce of complement. After 
an incubation period of 30 min at 37°C, the rabbit serum was 
assayed for residual hemolytic complement activity on sensi-
tized sheep erythrocytes. The results indicated that the anti-
bodies in the y, region, i.e., in pools 4 and 5, were capable oJ 
removing complement activity, presumably by activating the 
complement, but those in the Y2 region, i.e., in pool 2, were not. 
Thus, 2 classes of antibody that induced injury to the glo-
merulus by different mediating pathways were produced in 
sheep agy.inst rabbit GBM antigen. The first, induced by y, 
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FIG 3. Chromatographic separation of a globulin fraction (ammonium 
sulfate) on DEAE-Sephadex A-50 of the same sheep antirabbit glo-
merulru' basement membrane shown in Fig 2. Pooled fractions are 
shown. D.D. = outside diameter. 
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FIG 4. Proteinuria induced by injection of 2 fractions (pools 2 and 5) 
obtained by chromatography of sheep a ntirabbit glomerular basement 
membrane (anti-basement-membrane ABM) as noted in Fig 3. 
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antibodies, activated the complement system and attracted 
neutrophils to the site of injury. The injury was in great part 
dependent upon the action of neutrophils, although when more 
of the Yl antibody was employed, injury was in the absence of 
neutrophils. Whether a subclass of antibody is responsible for 
this neutrophil-independent injury is unknown. The second 
mediating pathway induced by Y2 antibodies produced injury 
independently of neutrophils. 
A Potential Role of Neutrophils in the Injury of the 
Glomerulus Induced by Immune Complexes 
Injury of the glomerular fIlter without requirement for neu-
trophils has also been observed in immune-complex glomeru-
lonephritis. In acute immune-complex disease (serum sickness) 
of rabbits, injury of the glomerulus develops despite removal of 
neutrophils [7]. The antigen-antibody complex is observed in 
the glomeruli along the GBM, and endothelial swelling and 
proteinuria fully develop (Table I). By contrast, the arteritis of 
serum sickness is markedly inhibited in neutropenic rabbits. 
In chronic immune-complex disease in rabbits, a varied pic-
ture is seen in which the accumulation of neutrophils in the 
glomeruli varies. In typical chronic immunologic membranous 
nephritis of rabbits, neutrophils are infrequently seen. In all 
cases, abundant deposition of C3 is observed in the glomeruli. 
PATHOGENESIS OF NEUTROPHIL-
INDEPENDENT IMMUNOLOGICAL 
RENAL INJURY 
Neutrophil-independent injury of the glomerulus after bind-
ing of anti-GBM antibody or deposition of immune complexes 
is now a well-known entity and may be of greatest importance 
in glomerular injury in diseases of human beings. The patho-
genetic mechanisms responsible are unknown, although a num-
ber of investigators have tried to elucidate them. The potential 
role of several mediation systems is discussed below. 
The Complement System 
Avian antibody to rat GBM induced proteinuria in the ab-
sence of complement fixation [8,9]. In the studies presented 
above, in which sheep antibody to rabbit GBM was used, the 
Y2 antibody of pool 2 also did not consume rabbit complement. 
When either the Y2 antibody of pool 2 or the Yl antibody of 
pools 4 and 5 was injected into neutrophil-depleted rabbits 
(HN2) that were also depleted of C3 and terminal components 
with cobra venom factor, strong proteinuria was observed. 
Similarly, the unfractionated antibody, injected into neutrophil-
depleted C6-deficient rabbits, also brought about proteinuria 
identical to that in neutrophil-depleted control rabbits. Thus, 
the sheep antirabbit GBM antibody produced glomerular injury 
in the absence of the lytic effects of complement and in rabbits 
depleted of over 95% of C3 and terminal components. 
Complement (C3) may also have bound with antibody along 
the GBM in rabbits, but in the absence of neutrophils, no 
detectable proteinuria was induced. This phenomenon was 
observed in rabbits receiving sheep anti-GBM obtained early 
in the course of immunization. As noted in Table I and Fig 4 
(pool 5), antibody (anti-basement-membrane [ABM]) was 
bound to glomeruli (between 50 and 100 Mg) and yet no protein 
appeared in the urine. The binding of abundant C3 along with 
sheep Y globulin in the glomeruli was observed with immuno-
TABLE I. Effect of neutrophil and C3 depletion on the lesions of 
acute immune-complex disease 
Arteritis Glomerulonephritis 
Group Proteinuria No. pos/total No. pos/total (mg/24 hr) 
Control 20/34 43/45 456 
Neutrophil-depleted 0/23 27/27 356 
C3-depleted (CoF) 0/6 13/13 664 
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fluorescence techniques. In other studies, Fish et al [10] and 
Wilson and Dixon [11] observed increased binding of rabbit C3. 
in glomeruli of rabbits recovering from acute serum sickness. 
The rabbits exhibited no proteinuria at a time when C3 depo' 
sition in the glomeruli was maximal. Most immunoglobulin 
deposition was less apparent at this time. Thus, in 2 forms of 
!mmunolo~ic gloI?~rulonephritis, complement may be depos' j Ited and WIthout Injury of the GBM being detectable. 
A poor correlation between complement deposition and 
GMB injury has been noted in other experimental systems. In 
guinea pigs with experimental glomerulitis induced by immu' 
nization with human GBM, only small amounts of C3 were 
found in two-thu'ds of both proteinuric and nonproteinuric 
animals [12,13]. In one-third of the proteinuric guinea pigs, no 
C3 was observed in the glomeruli. Anti-GBM antibody eluted 
from injured glomeruli failed to cause deposition of C3 in 
recipient normal guinea pigs despite deposition of large quan' . 
tities of IgG of both YJ and Y2 classes. In fm-ther studies by 
Couser, Stilmant, and Jermanovich [14], sheep anti-guinea-pig 
GBM caused immediate proteinuria in C4-deficient guinea pigs 
and in guinea pigs depleted of C3-9 with cobra venom factor. 
The sheep antibody did not fix guinea pig C3 or C4 in vitro or 
in vivo. Simpson et al [15] also found that proteinuria developed 
in cobra-venom-treated and C4-deficient guinea pigs after in' I 
jection of sheep anti-GBM. Immunofluorescence observations 
also showed deposition of C3 to be minunal or absent. In other 
studies, Passos et al [16] found that guinea pig antibodies to rat 
GBM predominantly of the yJ class produced proteinuria in 
recipient rats with minimal or no change in CH50 in the seruJ1l 
of recipients and no observable rat C3 in the glomerular lesion~· 
In acute immune-complex disease in rabbits, proteinurJ8, 
develops despite depletion of C3 and terminal components with 
cobra venom factor (Table I). The immune complexes are 
deposited in the glomeruli from the circulation despite comple· 
ment depletion. No difference in quantity of deposited corn' 
plexes could be detected by immunofluore!;lcence assay; C3 aod 
immune complexes were present in glomeruli of normal animalS. 
but C3 was absent in the immune-complex deposits in cobrw 
venom-factor-treated rabbits. 
Thus, with both anti-GBM- and immune-complex-induced , 
glomerulonephritis, an intact complement system is not esseV' 
tial for the development of neutrophil-independent injury. In 
addition, in those instances in which complement can be shoWP 
to interact at the level of the GBM but without the occurrence 
of measurable proteinuria, it would appear that the lytic actioP 
of the attack phase of complement does not sufficiently alter 
the GBM to allow passage of proteins. 
Fibrinogen and Fibrin and the Development of Glomerular 
Basement Membrane Injury in Immunologic 
Glomerulonephritis 
In severe nephrotoxic nephritis, fibrin may be observed j)1 
the capillaries of glomeruli. In moderate to mild glomerulone· 
phritis, fibrin is infrequently found. Similarly, in acute immune' , 
complex disease, little fibrinogen/fibrin is found in the diseased 
glomeruli. With an intact fibrinolytic system, the possibility 
must be considered that the fibrin in glomerular capillary 100PJ 
is rapidly degraded, swept away in the blood stream, aP. 
therefore not observed in mild glomerulonephritis. When tb¢ 
possibility is coupled with the observation that fibrinogen peP' 
tide E possesses vascular permeability-inducing activity, the 
fibrinogen-fibrin system takes on potential importance in tVe 
development of injury to the glomerulus. Three forms of injurY 
must be considered when studying the potential role of fibriw 
ogen/fibrin, the enzymes of the intrinsic and extrinsic clottiJ1~ 
system, and fibrinolytic enzymes. The forms of injury thai 
currently can be delineated include (a) damage or alteration.of 
the GBM mediated by neutrophils, (b) damage OCCUlTing III' 
dependently of neutrophils, and (c) crescent formation avd 
glomerular sclerosis. 
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Experiments dealing with the role of fibrinogen/ fibrin are 
discussed below, with these mechanisms as guidelines. The 
separations are necessary since coagulation or fibrinolysis could 
participate in one form of injury but not another; if a separate 
accounting of the forms of injury were not kept, the role of 
coagulation might be obscured. 
Nephrotoxic (Anti-GBM) Nephritis 
Early evidence in experimental animals suggested a role of 
fibrin/fibrinogen in glomerular permeability after injection of 
anti-GBM serum into rabbits. Using massive doses of heparin, 
Halpern et al [17] observed a diminution in proteinuria in 
treated rabbits; however, their results are difficult to interpret 
because of the minimal effect of the anti-GBM (only traces of 
proteinuria developed) and because of the lack of quantitative 
information provided on the amount of antibody bound in vivo. 
The inhibitory effect of heparin on proteinuria has not been 
substantiated in other studies [18-20]. It was apparent that 
heparin did not prevent fibrin deposition in glomeruli even 
when employed in massive doses. Thus, one must be guarded 
in making conclusions based on experiments in which heparin 
was used as an anticoagulant. Except in the study by Border, 
Wilson, and Dixon [20], neutrophil-independent and -depend-
ent pathogenetic mechanisms were not considered. Thus, neu-
trophil injury could overcome a potentially protective effect of 
the anticoagulation achieved with the heparin. 
Additional experimental observations argue against a role of 
fibrinogen/ fibrin in the development of glomerular permeabil-
ity in immunologic glomerulitis. Vassalli and McCluskey [21] 
employed dicoumerol to remove activity of the vitamin-K-de-
pendent coagulation proteins and showed that although cres-
cent formation and sclerosis were diminished (see below), pro-
teinuria was not. Employing the enzyme ancrod, derived from 
Malayan pit viper venom (which cleaves the B peptide of 
fibrinogen), Naish, Evans, and Peters [22,23] depleted clottable 
fibrinogen prior to injection of sheep anti-GBM. The amount 
of anti-GBM found in the kidneys was related to the proteinuria 
in the first 24 hr in normal and ancrod-treated rabbits. No 
diminution in proteinuria per microgram of antibody bound 
was observed. Because neutrophils were present and accumu-
lated in the glomeruli within 3 hr of injection of anti-GBM in 
both groups of rabbits, it was not possible to determine if the 
lack of effect of ancrod treatment involved neutrophil-depend-
ent or -independent injury of the GBM. Naish et al [22,23] also 
stated that endothelial proliferation in both the heterologous 
phase of nephrotoxic nephritis and serum sickness was undi-
minished in ancrod-treated rabbits. Similarly, when mice 
treated with anticoagulant were treated with urokinase for 
stimulation of fibrinolytic activity, glomerular injury with anti-
GBM was observed [24]. 
In summary, fibrinogen/ fibrin do not appear to be essential 
to the occurrence of GBM injury in situations in which neutro-
phils participate in nephrotoxic nephritis. The role of fibrin and 
fibrinogen in the development of neutrophil-independent GBM 
injury in nephrotoxic nephritis is still unclear since data on 
neutrophil-depleted animals are unavailable. 
Coagulation and Glomerular Injury in Acute Immune-
Complex Glomerulonephritis (Serum Sickness) 
In acute serum sickness, the injw'y of the GBM, with its 
associated proteinuria, is mediated by mechanisms independent 
of neutrophils and the terminal components of complement as 
noted above. Crescent formation and sclerosis do not take place 
in the acute form of this disease. Thus, studies on a role of 
coagulation and fibrin deposition in acute serum sickness could 
apply to neutrophil-independent GBM injury. An initial study 
on acute serum sickness by Baliah and Drummond [25J, in 
which the coagulatory ability of rabbits was blocked with 
warfarin sodium, revealed histological glomerular changes that 
occurred equally in treated and control groups. Unfortunately, 
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the extent of inhibition of fibrin formation in the rabbits was 
not assessed; a lowering of the one-stage prothrombin time was 
the sole reference assay. In addition, more of the treated than 
the control rabbits showed fibrinogen/ fibrin in the glomeruli. 
Naish et al [23J employed the fibrinogen-depleting enzyme 
ancrod to study the role of coagulation in morphological and 
immunologic changes in acute serum sickness. Morphological 
changes in glomeruli were unaffected by fibrinogen depletion. 
(Values for proteinuria were not presented.) 
Border et al [20] observed that, in chronic immune-complex 
glomerulonephritis, massive heparin treatment failed to alter 
the course of the disease. Unfortunately, heparin did not pre-
vent fibrinogen/ fibrin deposition in the lesions, and thus the 
data, as noted by the authors, speak neither for nor against a 
role of fibrin deposition. In McGiven's experiments [26] on 
spontaneously developing chronic immune-complex disease in 
female NZB/ NZW mice, anticoagulation with warfarin sodium 
starting at 4 months of age failed to influence the progress of 
the disease. 
Thus, in acute imune-complex injury of the glomerulus, the 
studies reported suggest that fibrin formation in the glomerulus 
does not playa role in the development ofinjw-y. Unfortunately, 
the available data are incomplete, and a final conclusion cannot 
yet be drawn. 
Vasoactive Amines in Immunologic InjUly of the Glomerular 
Basement Membrane 
Permeability of the GBM resulting from an antibody-antige'n 
reaction was rendered by vasoactive amines. Results of assays 
with antagonists of histamine and serotonin have been uni-
formly negative, however. In my laboratory, 10 mg/ kg of the 
antihistamine chlorprophen-pyridamine maleate (Chlor-Tri-
meton) and 0.5 mg/ kg of the serotonin antagonist methysergide 
maleate in rabbits failed to inhibit the proteinuria caused by 
injection of sheep antirabbit GBM [27]. In guinea pigs given 
injections of sheep anti-GBM, which induces injury largely 
independently of neutrophils, several antagonists of histamine 
and serotonin have been tested; promethazine, chlorophenira-
mine, and cyproheptadine failed to diminish the proteinuria 
occurring in the ·fu·st 24 hr [14,15]. 
In active immune-complex disease, the role of vasoactive 
amines in GBM injury could not be evaluated because of the 
inhibition of deposition of the circulating immune complexes 
occurring in the presence of their antagonists [27]. 
Cells Potentially Involved in InjUly of the GEM 
The role of neutrophilic leukocytes in immunologic injury 
has been described above. In anti-GBM disease in rabbits, 
depletion of platelets failed to diminish proteinuria [27], al-
though the assays were not performed in neutrophil-depleted 
animals. The role of platelets in neutrophil-independent injury 
is therefore unresolved. In acute immune-complex disease (se-
rum sickness) , removal of platelets limited the glomerular dep-
osition of the circulating complexes, and therefore the agents 
that initiate the disease [27]. Thus, the participation of platelets 
in GBM injury has not been adequately evaluated. 
A role of mononuclear cells has been recently investigated in 
an accelerated form of nephrotoxic nephritis in rats. After 
preimmunizing rats to rabbit IgG and then injecting rabbit and 
antirat GBM, Schreiner et al [28J noted an acceleration in 
glomerular injury. During the first 24 hr after injection of anti-
GBM, proteinuria that was associated with the glomerular 
accumulation of complement and neutrophils resulted. Between 
48 and 96 hr, when neutrophils were almost entirely absent in 
the glomeruli, mononuclear cells were observed in the glomer-
uli. These cells, morphologically identifiable as monocytes and 
macro phages by electron microscopy, apparently arose from 
r,recursors originating outside of the kidney as determined by 
. H-thymidine labeling experiments. Irradiation of the rats (their 
kidneys were shielded) greatly diminished the accumulation of 
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the mononuclear leukocytes in glomeruli and the amount of 
proteinuria on day 2 (6.8 ± 3.9 mg/24 hr in irradiated rats and 
20.3 ± 3.2 in controls) and day 4 (3.9 ± 4.8 mg/24 hr in irradiated 
and 28.7 ± 5.5 in control animals). These are most promising 
results and may explain at least in part the neutrophil-indepen-
dent proteinuria observed in experimental animals. 
Resident cells, primarily the endothelial and mesangial ele-
ments, may also contribute to alteration of the GBM leading to 
proteinuria. Data pertaining to this possibility are not available. 
POTENTIAL INJURY OF THE GLOMERULAR 
BASEMENT MEMBRANE BY THE BINDING OF 
ANTIBODY ALONE 
The possibility must be considered that injury to the GBM 
and proteinuria result from the binding of immunoglobulins to 
the GBM. In our studies at Scripps, 2 experimental observations 
suggested that this is not the case. When Y2 globulin of pool 1 
(Fig 3) was examined for its ability to bind to the GBM in vivo 
and to induce injury, no proteinuria resulted when amounts of 
antibody comparable to those in pool 2 or pools 4 and 5 were 
employed. :rhe amount of binding antibody of pool 1 was then 
increased to 5 times that of pool 2 and again the antibody failed 
to induce proteinuria (Table II) . In another experiment, we 
subjected unfractionated antibody globulin to papain hydrolysis 
and reduction to obtain F Ab fragments. These were radiola-
beled with 1251 and injected into rabbits. Binding of the FAb up 
to 10 times that of the whole, unfractionated IgG failed to 
induce proteinuria. Similarly, Simpson et al [15] found that the 
pepsin-cleaved (F Ab') of sheep YI nephrotoxic antibody and the 
papain-produced (FAb) of the same antibody failed to induce 
proteinuria in guinea pigs. By contrast, injection of F(ab'h YI 
antibodies resulted in amounts of proteinuria comparable to 
those in guinea pigs given injections of native antibody. Kobay-
ashi, Shigematsu, and Tada [29], who used F(ab'h of guinea 
pig YI antibody, made similar observations. Their data indicate 
that both combining sites are essential on the antibody mole-
cule, but that the Fc fragment, cleaved from the molecule by 
pepsin, is not essential. 
Couser et al [14] reported that heterologous sheet antibody 
to guinea pig GBM can react in vivo to produce, in the fIrst 24 
hr, transient proteinuria that subsides despite the continued 
presence of heterologous Ig on the GBM. Immunization of such 
guinea pigs with sheep Ig induced antibody responses to the 
heterologous sheep Ig and deposition of autologous Ig along the 
GBM. Nevertheless, no proteinuria resulted. Single or repeated 
passive injection of autologous guinea pig or heterologous rabbit 
antibody to the GBM-deposited sheep Ig resulted in strong 
(4+) linear deposits of the injected antibody on the guinea pig 
GBM but failed to induce proteinuria. These data suggest that 
the binding of immunoglobulins alone does not necessarily 
induce proteinuria. 
The foregoing describes the CUTI'ent state of knowledge re-
garding one form of inflammatory injury. It should be clear, 
however, that this is not a specialized event, but rather is not 
at all unlike other forms of inflammation. It would not be 
surprising to find many of the features of glomerular inflam-
mation present in inflammation of other tissues. In fact, the 
complement-neutrophil dependent mechanism of injury is seen 
in cutaneous vasculitis, arteritis, and synovitis. Neutrophil-in-
dependent edema may be observed in active Arthus reactions. 
THE HAGEMAN FACTOR PATHWAYS 
The role of the components of the HF system in the patho-
genesis of inflammation is poorly understood. In order to ex-
amine the potential participation of the system in inflammation, 
investigators have conducted abundant studies in the past 
several years to delineate the component proteins and examine 
the mechanism of their interaction. 
The components of this system (Fig 5) consist of a series of 
proenzymes that, on activation, act sequentially to generate 3 
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distinct processes: the generation of kinins, the generation of 
fibrin, and the generation of fIbrinolysis. 
Activation of components of the pathways is associated with 
limited proteolytic cleavage of each component. This associa-
tion may be exemplified by the action of activated HF on its \ 
substrates, i.e., on prekallikrein and factor XI. In each case, the 
substrate is cleaved initially into 2 subunits as activation takes 
place. In our laboratory, the position of cleavage has been 
documented in each of the proteins and the fragments resulting 
have been characterized. Similarly, with HF the activation in 
plasma is accompanied by cleavage. With HF and prekallikrein, 
the initial cleavage occurs at 2 closely related positions on the \ 
peptide chain, one of which lies within a small disulfide loop. 
The biological meaning of the 2 cleavage sites is discussed 
below. 
Although the mechanism by which the HF system partici· 
pates in the development of inflammation are not understood, \ 
ample evidence indicates that each cardinal sign of the inflam· 
matory process can be expressed by activity of the system. \ 
Inflammatory activities mediated by components ofthe systems 
are listed in Table III. 
Knowledge about the relationship of components of the HF 
pathways to development of tissue injury has been handicapped 
by our inability to follow the individual molecules as they 
participate in the reactions. In order to follow them, it has been 
TABLE II. Lach of glomeru.lar inju.ry by an.ti ·basement·membrane 
eluted first from DEAE-Sephadex 
AMB bound 
("g) 
49 
168 
436 
Urine prote in 
(mg/20 hr) 
o 
o 
2 
HAGEMAN FACTOR 
HIGH MOLECULAR WEIGHT KININOGEN 
PREKALLIKREIN 
NEGATIVELY CHARGED SURFACE 
PRE-
KALL I KRE I N KALL I KRE I N 
KININOGEN KININ 
PLASMINOGEN 
CLOTTING 
FACTOR 
PLASM I N 
XI 
r 
INT. CLOT . 
CLOTTING 
FACTOR V Vila 
EJ. CLOT. 
SYSTEM SYSTEM 
F IG 5. The schematic representa tion of the Hageman FactoI' system.\ 
Int . Clot. = intrinsic clotting; Ext. Clot. = extrinsic clotting. 
TABLE III. Biological activities attributed to the Hageman factor 
systems 
Inflammatory activity 
Increased vascular permeabili ty 
P ain 
Hypot.ension 
Chemotaxis of neutrophils 
Smooth muscle contraction 
Fibrin formation (coagulation) 
C1 (complement) activation 
Componen ts responsible 
Bradykinin 
Histidine-rich peptide ofHMWK\ 
Fibrinogen fragment E 
Active HF (PF / dil) 
Bradykinin 
Bradykinin 
Kallikrein 
Fibrinogen fragment D 
C3 cleaved by plasmin 
Bradykinin 
Combined activity of HF, 
HMWK, kaUilu'ein, and factor 
XI (intrinsic clotting systeml 
Active HF- factor VII (extrinsir 
clotting system) 
Plasmin 
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essential to pmify the molecules and to prepare the purified 
proteins labeled with radioactive iodine. In addition, a fIrm 
understanding of the molecular mechanisms of activation of 
each component of the various pathways and of the molecular 
interactions involved in the ' activation is essential. Several 
laborat~ries have devoted considerable attention to these prob-
lems, and data that have expanded om understanding have 
emerged. Several recent reviews on these topics have appeared 
[30-33]. 
The HF zymogen can be isolated as a single polypeptide 
chain of a mol wt of 76,000 to 80,000 (determined on polyacryl-
amide gels in the presence of sodium dodecyl sulfate [34]) . 
Proteolytic activation of HF by kallikrein, plasmin, or trypsin 
yields a species, with a mol wt of 28,000, that contains the 
enzymatic active site [35-39] and 52,000 mol wt or 40,000 
mol wt fragments that bind avidly to negatively charged, acti-
vating surfaces but that do not contain an active site [40]. 
ACTIVATION OF HAGEMAN FACTOR 
BY SURFACE CONTACT 
Studies on the mechanisms of smface-dependent activation 
of HF have been pelformed with pmifIed proteins and an 
activating surface, such as kaolin. Hypotheses based on such 
studies have then been tested in vitro in plasma as well as in 
vivo with activating agents that are more biologically relevant 
than kaolin. 
The importance of prekallikrein to the activation of HF was 
recognized when it was shown that kallikrein could proteolyti-
cally activate HF [39], that rabbit kallikrein could stimulate 
clotting of rabbit plasma [41], and that Fletcher plasma, defI-
cient in prekallikrein [42,43], exhibited abnormal surface-acti-
vated reactions [44,45]. 
Role of High-Molecular- Weight Kininogen in the Contact 
Phase of Activation 
More recently, plasma defIcient in high-molecular-weight 
kininogen (HMWK) [46] (this defIciency is known as the Fitz-
gerald [47,48], WilJiams [49], or Flaujeac trait [46]) has been 
shown to be incapable of contact activation of HF. The HMWK 
had also been studied under the name of "contact activation 
cofactor" [50,51]. These observations led co-workers and I to 
conduct a series of experiments, on which we based a hypothesis 
for the mechanism of surface activation of HF [52]. 
One can conveniently determine the activation of HF by 
using clotting assays to measme the ability of activated HF 
(denoted as HF,,) to generate factor XI". The ability of various 
combinations of pmified HF, HMWK, prekallikrein, and kaolin 
to activate partially pmifIed factor XI in an incubation mixtme 
was studied in experiments in which the factor XI. formed 
dming an 8-min incubation at 37°C was measmed. The results 
show that efficient conversion offactor XI to factor XI" requires 
HF, HMWK, prekallikrein, and kaolin. For example, omission 
of either prekallikrein or HMWK gave 10-fold less activation of 
factor XI [52]. In subsequent studies, a mixture of pmified HF, 
HMWK, prekallikrein, and kaolin gave the same rapid rate of 
activation of purified factor XI as an equivalent aliquot of 
factor-XI-deficient plasma. This fact suggested that potent, 
surface-mediated activation of factor XI in plasma is explicable 
in terms of HF, HMWK, and prekallikrein [52]. 
We used the same experimental system to demonstrate that 
HMWK exerts its effect on the activation of HF in a stoichio-
metric rather than a catalytic manner. Optimal effects of 
HMWK in stimulating activation of HF occurred when nearly 
equal quantities of the two proteins were present on the kaolin. 
We therefore hypothesized that HF and HMWK form stable, 
surface-bound complexes with each other. 
After the observation that HMWK is essential for the rapid 
activation of HF on kaolin, it was important to determine the 
mechanism by which this stimulation was exerted. Because a 
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combination of HF, prekallikrein, and HMWK was essential for 
activation of HF on the surface, we designed experiments to 
find out: (a) whether HMWK stimulates the action of active 
kallikrein on smface-bound HF, (b) whether surface-bound, 
active HF, i.e., HF", activates prekallikrein more rapidly in the 
presence of HMWK, and (c) whether HMWK promotes the 
activation of factor XI by smface-bound HF". 
In brief, these experiments demonstrated that HMWK (a) 
augments by 10- to 20-fold the enzymatic action of kallikrein 
on smface-bound HF and (b) augments by over lO-fold the 
activation of both pre kallikrein and clotting factor XI by sm-
face-bound active HF [52]. Similar data have been reported 
from other laboratories [53]. In the fluid phase, a modest 
enhancement of activation was also observed [54]. 
The mechanism by which HMWK stimulates contact acti-
vation of HF, prekallikrein, and factor XI has received fwther 
attention. Prekalliluein was found to circulate in a high-molec-
ular-weight form [55]. In recent studies, Kaplan and his col-
leagues elegantly demonstrated that pre kallikrein [56] and fac-
tor XI [57] actually form complexes with HMWK in whole 
normal plasma. We have further observed that the HMWK 
acts by bringing the pre kallikrein and factor XI to the smface 
as these latter molecules have little affinity for the surface in 
the absence of HMWK [58]. In the presence of HF on the 
surface, the pre kallikrein and factor XI then undergo cleavage 
into their characteristic heavy and light chains. Molecular 
models of this phenomenon are shown in Fig 6 and 7. 
MOLECULAR ASSEMBLY IN CONTACT ACTIVATION 
lR 
® 
+ -\' 
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FIG 6. Moleculru' model for the binding of components of the Hage-
man (HF) system to a negatively charged sUl'face. Although HF (factor 
XII) can bind by itself, prekallikrein (PK) and clotting factor XI (XI) 
require high-molecular-weight Kininogen (HMWK) to bring them to 
the negatively chru'ged surface. 
2 
Surface 
FIG 7. This figure shows the binding of Hageman Factor (HF) and 
the complex of prekalliluein and high-moleculru'-weight Kininogen 
(HMWK) to the surface. Prekallikrein (PK) and HF then undergo 
activation. 
46 COCHRANE 
THE ASSOCIATION OF CLEAVAGE 
OF HAGEMAN FACTOR 
WITH ITS ACTIVATION 
Plasma containing 125I_HF was subjected to contact activa-
tion in glass tubes, and both the binding of 125I_HF in plasma to 
the activating glass surface and the cleavage of the 125I_HF 
during contact activation were studied [59]. The kinetics of 
cleavage of 125I_HF in normal, prekallikrein-deficient (Fletcher), 
and HMWK-deficient (Fitzgerald) plasma is seen in Fig 8. In 
normal plasma, rapid cleavage of HF (which plateaus at 60%; 
see Fig 8) occurs and is complete within 5 min. The remaining 
40% ofHF molecules that are not cleaved are in the supernatant 
[59], that is, when there is a limiting amount of surface, binding 
of HF to the surface is a prerequisite for cleavage. In contrast 
to the rapid cleavage of HF seen in normal plasma, plasma 
deficient in pre kallikrein or HMWK does not exhibit rapid 
cleavage of HF (Fig 8), though a slow cleavage over a long 
period of time is evident. 
The failure of the HF to be cleaved rapidly in glass tubes in 
plasma deficient in pre kallikrein or HMWK did not occur as a 
result of failure to bind to the activating surface. Fig 9 shows 
the kinetics of binding and of cleavage of 125I_HF during the 
first 120 sec of incubation, expressed at the percent of total HF 
present that was cleaved or bound. The kinetics of HF binding 
was the same for normal, prekallikrein-deficient, and HMWK-
deficient plasmas. Cleavage (Fig 8) was rapid in normal plasma 
but was not observed in the deficient plasma. Cleavage of HF 
in factor-XI-deficient plasma occurred at a rate equal to that in 
normal plasma. 
Reconstitution of the respective deficient plasmas with prek-
allikrein and HMWK restored the rapid rate of cleavage of 1251_ 
HF on exposure of the plasma to glass [59,60]. 
In additional experiments designed to determine whether 
surface contact alone induced activation of HF, purified HF 
was exposed to kaolin in the presence or absence of purified 
kallikrein or trypsin. 3H diisopropylphosphofluoridate eHDFP) 
was then added and it was found that little or no 3HDFP was 
taken up into the HF. By contrast, when kallikrein or trypsin 
was added, the HF was cleaved into 52,000 and 28,000 mol wt 
fragments, and 3HDFP was taken up stoichiometrically into the 
28,000 mol wt fragment of the HF. These data strongly suggest 
that cleavage of HF is essential for activation of the molecule. 
BIOLOGICAL ACTIVITIES ASSOCIATED WITH 
POSITIONS OF CLEAVAGE OF 
HAGEMAN FACTOR BY KALLIKREIN 
Further studies have been performed on the cleavage of \251_ 
HF. In the presence or absence ofreducing agents, the HF was 
found to be cleaved by kallikrein at 2 closely positioned sites 
(within 10 to 15 residues' distance), one of which fell within a 
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FlG 8. Rate of cleavage of 125I_Hageman Factor (HF) in normal, 
prekaHikrein-deficent (prekallikrein·def) (Fletcher), and high-molec-
ular-weight Kininogen-deficient (HMWK·def) (Fitzgerald) plasma in 
glass tubes. The 20-/LI aIiquots of plasma (diluted '1:6) were shaken in 
glass tubes at 20°C, and the extent of cleavage of 125I_HF was measured 
with sodium dodecyl sulfate gel electrophoresis. . 
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disulfide loop. Cleavage at both sites' rendered the molecule 
activated (Fig 10). These cleavage patterns were also demon· 
strated in whole plasma [60]. 
Cleavage within the disulfide loop left the molecule, in its \ 
native molecular weight, attached to the activating surface; 
cleavage outside the loop allowed the 28,000 mol wt active 
fragment to dissociate from the surface. The intact, activated 
HF was termed lX-HF3 ; the dissociated fragment was called p. 
HF" [61]. The lX-HF" was then found to activate both factor Xl 
and pre kallikrein on the surface; the ,B-HF" was found to 
activate only prekallikrein. In further studies, factor XI after \ 
activation was found to remain bound to the surface, but 
kallikrein was readily dissociated [58,61]. 
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FIG 9. Kinetics of binding and cleavage of 125J_HF in normal, pre· 
kallikrein-deficient (prelzallikrein·def), and high-moleculm'-weight 
Kininogen-deficient (HMWK-def.) plasmas in glass tubes. The solidI 
lines denote binding; the dashed lines indicate cleavage. 
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FIG 10. Characteristics of Hageman Factor (HF) and its activated 
forms produced during contact activation of plasma. Two forms of HF. 
are defined by cleavage qf the native zymogen at specific sites. The 
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indicated. Neg. = negatively charged. 
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These studies indicate that the activation of factor XI and 
therefore the intrinsic clotting system are contained at the point 
of activation on the surface. By contrast, since /3-HFn, which 
principally activates pre kallikrein, and kallikrein are rapidly 
dissociated from the surface, the kinin-forming and fibrinolytic 
activities of the systems are rapidly disseminated. Molecular 
models of these relationships are shown in Fig 11 and 12. 
Surface 
Intrinsic Clotting 
System 
Surface 
FIG 11. Activation of the intrinsic clotting system. The IX-Hageman 
Factor (XII) on the surface activated factor XI, which remains bound 
to the high-molecular-weight factor (HMWK). Kallikrein (K), however, 
with its lower affinity for the HMWK, dissociates from the latter 
molecule. Factor XI on the surface then activates factor Xl and thus 
sets into modon the intrinsic clotting system. 
Extrinsic 
Clotting 
System 
Surface 
Fibrinolysis 
Bradykinin IBk] 
Release 
FIG 12. Fluid phase: activation of the fibrinolytic, extrinsic clott ing, 
and bradykinin systems. The ,B-Hageman Factor (XII) is released into 
the supernatant by virtue of cleavage by kallikrein (K) occurring outside 
of the disulfide loop (Fig 10). The ,B-HF. then activates additional 
prekallikrein (PK) as well as factor VII in solution. Kallikrein (K) in 
solution activates plasminogen (PLG) to plasmin (PLS) (and thereby 
stimulates fibrinolytic activity) and cleaves bradykinin (BII) from kini-
nogen (Kgn) . 
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Stimulation of human lung fragments or leukocyte prepara-
tions with anti-IgE or, in cases of allergic individuals, with 
specific antigen has recently been found to induce release of 
kallikrein enzymes [62]. In collaborative studies, we have sought 
to link the release of these kallikreins with the generation of 
HF activity in vitro. Together with Dr. H. H . Newball, we have 
demonstrated surface-augmented specific cleavage of HF by 
purified lung and leukocytic kallikrein [63]. In related studies, 
Weese et al [64] observed that alveolar washings of normal 
Syrian golden hamsters contained immunoreactive bradykinin. 
Hexadimethrine, added to prevent HF activation, blocked the 
generation of kinin. The mechanism by which the system of 
proteins in the isolated lung was activated was unclear. 
In other studies, Movat and his colleagues demonstrated that 
the cleavage of kininogen releases kinins by means of enzymes 
of neutrophilic leukocytes [65]. In our laboratory, activated 
platelets have recently been found to provide an activating 
surface for HF [66]. Hageman factor was cleaved into 52,000 
and 28,000 mol wt fragments by kallikrein on the surface of 
platelets that had been activated by exposure to ADP or 
collagen. 
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